A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer

Indian Journal of Human Genetics

Volumn 17, Issue 3, 2011, Pages 132-144

  Chattopadhyay, Koushik ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Cervical cancer; genetics; HPV; polymorphism; progression

Indexed keywords

CHEMOKINE RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME P450 1A1; CYTOCHROME P450 2D6; FAS LIGAND; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HOST FACTOR; INTERLEUKIN 10; LEUKOCYTE ANTIGEN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); P21 ACTIVATED KINASE; PROTEIN P53; TUMOR NECROSIS FACTOR;

CANCER GROWTH; DATA BASE; GENETIC SUSCEPTIBILITY; HEREDITY; HLA SYSTEM; HUMAN; MEDLINE; PAPILLOMAVIRUS INFECTION; REVIEW; RISK FACTOR; UTERINE CERVIX CANCER;

HUMAN PAPILLOMAVIRUS;

EID: 84856383345     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.92087     Document Type: Review

References (204)

1. Castellsague XS, de Aguado S, Louie D, Bruni KS, Munoz L, Diaz J, et al. HPV and cervical cancer in the world 2007 report. Vaccine 2007;26:S3.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. (Pubitemid 33586866)
3. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: The global picture. Eur J Cancer 2001;37 (Suppl 8):S4-66.
4. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003;3:469-75. (Pubitemid 36919093)
5. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature 1999;400:29-30.
6. Hemminki K, Dong C, Vaittinen P. Familial risks in cervical cancer: Is there a hereditary component? Int J Cancer 1999;82:775-81. (Pubitemid 29384324)
7. Zhu M, Zhao S. Candidate gene identification approach: Progress and challenges. Int J Biol Sci 2007;3:420-7. (Pubitemid 350132789)
8. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: Practical considerations. Nat Rev Genet 2002;3:391-7. (Pubitemid 34506720)
9. Duggan-Keen MF, Keating PJ, Stevens FR, Sinnott P, Snijders PJ, Walboomers JM, et al. Immunogenetic factors in HPV-associated cervical cancer: Influence on disease progression. Eur J Immunogenet 1996;23:275-84. (Pubitemid 26254666)
10. Hildesheim A, Schiffman M, Scott DR, Marti D, Kissner T, Sherman ME, et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: Results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:1035-41. (Pubitemid 28514105)
11. Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: Results from a population-based study in Costa Rica. J Infect Dis 2001;184:1310-4. (Pubitemid 33055576)
12. Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ. HLA and susceptibility to cervical neoplasia. Hum Immunol 1999;60:337-42. (Pubitemid 29239568)
13. Chan PK, Cheung JL, Cheung TH, Lin CK, Tam AO, Chan DP, et al. HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women. Int J Cancer 2006;118:1430-5.
14. Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N. Cervical carcinoma: Human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenet 1998;25:329-37. (Pubitemid 28473099)
15. Silva B, Vargas-Alarcon G, Zuniga-Ramos J, Rodriguez-Reyna TS, Hernandez-Martinez B, Osnaya N, Kofman S, Torres-Lobaton A, Granados J. Genetic features of Mexican women predisposing to cancer of the uterine cervix. Hum Pathol 1999;30:626-628. (Pubitemid 29266719)
16. Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, et al. Spontaneous regression of high-grade cervical dysplasia: Effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005;11:4717-23. (Pubitemid 41557190)
17. Carreon JD, Martin MP, Hildesheim A, Gao X, Schiffman M, Herrero R, et al. Human leukocyte antigen class I and II haplotypes and risk of cervical cancer. Tissue Antigens 2005;66:321-4. (Pubitemid 41406671)
18. Chan DP, Cheung TH, Tam AO, Cheung JL, Yim SF, Lo KW, et al. Risk association between human leukocyte antigen-A allele and high-risk human papillomavirus infection for cervical neoplasia in Chinese women. J Infect Dis 2005;192:1749-56. (Pubitemid 41587825)
19. Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, et al. Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis 2002;186:598-605. (Pubitemid 34925531)
20. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-5. (Pubitemid 21912416)
21. Helland A, Borresen AL, Kaern J, Ronningen KS, Thorsby E. HLA antigens and cervical carcinoma. Nature 1992;356:23.
22. Wank R, Schendel DJ, Thomssen C. HLA antigens and cervical carcinoma. Nature 1992;356:22-3.
23. David AL, Taylor GM, Gokhale D, Aplin JD, Seif MW, Tindall VR. HLA-DQB1*03 and cervical intraepithelial neoplasia type III. Lancet 1992;340:52.
24. Wank R, Meulen JT, Luande J, Eberhardt HC, Pawlita M. Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLA-DQB1*0602,*301,*0303 alleles. Lancet 1993;341:1215. (Pubitemid 23137141)
25. Helland A, Borresen AL, Kristensen G, Ronningen KS. DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: Relationship to human papillomavirus infection and prognosis. Cancer Epidemiol Biomarkers Prev 1994;3:479-86. (Pubitemid 24280971)
26. Mehal WZ, Lo YM, Herrington CS, Evans MF, Papadopoulos MC, Odunis K, et al. Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis. J Clin Pathol 1994;47:1077-81.
27. Gregoire L, Lawrence WD, Kukuruga D, Eisenbrey AB, Lancaster WD. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int J Cancer 1994;57:504-7.
28. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Association between HLA DQB1 * 03 and cervical intraepithelial neoplasia. Mol Med 1995;1:161-71.
29. Nawa A, Nishiyama Y, Kobayashi T, Wakahara Y, Okamoto T, Kikkawa F, et al. Association of human leukocyte antigen-B1*03 with cervical cancer in Japanese women aged 35 years and younger. Cancer 1995;75: 518-21.
30. Apple RJ, Becker TM, Wheeler CM, Erlich HA. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J Natl Cancer Inst 1995;87:427-36.
31. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer 1996;67:595-602. (Pubitemid 26300972)
32. Sanjeevi CB, Hjelmstrom P, Hallmans G, Wiklund F, Lenner P, Angstrom T, et al. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996;68: 409-14. (Pubitemid 26414491)
33. Ferrera A, Olivo A, Alaez C, Melchers WJ, Gorodezky C. HLA DOA1 and DOB1 loci in Honduran women with cervical dysplasia and invasive cervical carcinoma and their relationship to human papillomavirus infection. Hum Biol 1999;71:367-79. (Pubitemid 29257229)
34. Cuzick J, Terry G, Ho L, Monaghan J, Lopes A, Clarkson P, et al. Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. Br J Cancer 2000;82:1348-52. (Pubitemid 30145357)
35. Neuman RJ, Huettner PC, Li L, Mardis ER, Duffy BF, Wilson RK, et al. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gynecol 2000;95:134-40. (Pubitemid 30001643)
36. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer 2001;93:817-22. (Pubitemid 32756751)
37. Dehaghani AS, Amirzargar A, Farjadian S, Ghaderi A. HLA-DQBl alleles and susceptibility to cervical squamous cell carcinoma in Southern Iranian patients. Pathol Oncol Res 2002;8:58-61. (Pubitemid 34532782)
38. Ghaderi M, Wallin KL, Wiklund F, Zake LN, Hallmans G, Lenner P, et al. Risk of invasive cervical cancer associated with polymorphic HLA DR/DQ haplotypes. Int J Cancer 2002;100:698-701. (Pubitemid 34832981)
39. Matsumoto K, Yasugi T, Nakagawa S, Okubo M, Hirata R, Maeda H, et al. Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 2003;106:919-22. (Pubitemid 37071671)
40. Engelmark M, Beskow A, Magnusson J, Erlich H, Gyllensten U. Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer. Hum Mol Genet 2004;13:1951-8. (Pubitemid 39214342)
41. Dao DD, Sierra-Torres CH, Robazetti SC, de Gomez MN, Konig R, Lema C, et al. HLA-DQB1 and cervical cancer in Venezuelan women. Gynecol Oncol 2005;96:349-54. (Pubitemid 40127133)
42. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Analysis of the entire HLA region in susceptibility for cervical cancer: A comprehensive study. J Med Genet 2005;42:e49.
43. Schiff MA, Apple RJ, Lin P, Nelson JL, Wheeler CM, Becker TM. HLA alleles and risk of cervical intraepithelial neoplasia among Southwestern American Indian women. Hum Immunol 2005;66:1050-6. (Pubitemid 43005007)
44. Wu Y, Chen Y, Li L, Cao Y, Liu Z, Liu B, et al. Polymorphic amino acids at codons 9 and 37 of HLA-DQB1 alleles may confer susceptibility to cervical cancer among Chinese women. Int J Cancer 2006;118:3006-11.
45. Lema C, Fuessel-Haws AL, Lewis LR, Rady PL, Lee P, Turbat-Herrera EA, et al. Association between HLADQB1 and cervical dysplasia in Vietnamese women. Int J Gynecol Cancer 2006;16:1269-77. (Pubitemid 43886756)
46. Wu Y, Liu B, Lin W, Xu Y, Li L, Zhang Y, et al. HPV16 E6 variants and HLA class II polymorphism among Chinese women with cervical cancer. J Med Virol 2007;79:439-46. (Pubitemid 46355445)
47. Bhattacharya P, Sengupta S. Predisposition to HPV16/18- related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens 2007;70:283-93. (Pubitemid 47340723)
48. Beskow AH, Moberg M, Gyllensten UB. HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. Int J Cancer 2005;117:510-4. (Pubitemid 41429577)
49. Chan PK, Cheung JL, Cheung TH, Lin CK, Siu SS, Yu MM, et al. HLA-DQB1 polymorphisms and risk for cervical cancer: A case-control study in a southern Chinese population. Gynecol Oncol 2007;105:736-41. (Pubitemid 46738579)
50. Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung CF, et al. HLA-DQB1*02-restricted HPV-16 E7 peptidespecific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 2007;13:2479-87. (Pubitemid 46698600)
51. Climent C, Nazario CM, Umpierre S, Quintero M, Gorbea S. Major histocompatibility complex class II polymorphisms and risk of cervical cancer in Puerto Rican women. P R Health Sci J 2007;26:97-101.
52. Sastre-Garau X, Loste MN, Vincent-Salomon A, Favre M, Mouret E, de la Rochefordiere A, et al. Decreased frequency of HLA-DRB1 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer 1996;69:159-64. (Pubitemid 26233291)
53. Gostout BS, Podratz KC, McGovern RM, Persing DH. Cervical cancer in older women: A molecular analysis of human papillomavirus types, HLA types, and p53 mutations. Am J Obstet Gynecol 1998;179:56-61. (Pubitemid 28394473)
54. Maciag PC, Schlecht NF, Souza PS, Franco EL, Villa LL, Petzl-Erler ML. Major histocompatibility complex class II polymorphisms and risk of cervical cancer and human papillomavirus infection in Brazilian women. Cancer Epidemiol Biomarkers Prev 2000;9:1183-91.
55. Cervantes J, Lema C, Valentina Hurtado L, Andrade R, Hurtado Gomez L, Torrico L, et al. HLA-DRB1*1602 allele is positively associated with HPV cervical infection in Bolivian Andean women. Hum Immunol 2003;64:890-5. (Pubitemid 37093461)
56. Sastre-Garau X, Cartier I, Jourdan-Da Silva N, De Cremoux P, Lepage V, Charron D. Regression of lowgrade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype. Obstet Gynecol 2004;104:751-5. (Pubitemid 40458804)
57. Mahmud SM, Robinson K, Richardson H, Tellier PP, Ferenczy AS, Roger M, et al. HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis 2007;196:82-90. (Pubitemid 46982741)
58. Chan PK, Cheung TH, Lin CK, Siu SS, Yim SF, Lo KW, et al. Association between HLA-DRB1 polymorphism, high-risk HPV infection and cervical neoplasia in southern Chinese. J Med Virol 2007;79:970-6. (Pubitemid 46871556)
59. Vandenvelde C, De Foor M, van Beers D. HLA-DOB1*03 and cervical intraepithelial neoplasia grades I-III. Lancet 1993;341:442.
60. Wu Y, Liu B, Lin W, Xu Y, Li L, Zhang Y, et al. Human leukocyte antigen class II alleles and risk of cervical cancer in China. Hum Immunol 2007;68:192-200. (Pubitemid 46356649)
61. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet 1994;6:157-62. (Pubitemid 24188596)
62. Allen M, Kalantari M, Ylitalo N, Pettersson B, Hagmar B, Scheibenpflug L, et al. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: Indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 1996;48:32-7. (Pubitemid 26318566)
63. Helland A, Olsen AO, Gjoen K, Akselsen HE, Sauer T, Magnus P, et al. An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102- DQB1*0602 haplotype: A population-based case-control study of Norwegian women. Int J Cancer 1998;76:19-24. (Pubitemid 28164563)
64. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, et al. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 2001;94:711-6. (Pubitemid 33035692)
65. De Araujo Souza PS, Villa LL. Genetic susceptibility to infection with human papillomavirus and development of cervical cancer in women in Brazil. Mutat Res 2003;544:375-83. (Pubitemid 37487680)
66. Yang YC, Chang CL, Chen ML. Effect of p53 polymorphism on the susceptibility of cervical cancer. Gynecol Obstet Invest 2001;51:197-201.
67. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34. (Pubitemid 28261713)
68. Andersson S, Rylander E, Strand A, Sallstrom J, Wilander E. The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas. Br J Cancer 2001;85:1153-6. (Pubitemid 33052314)
69. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999;354:218-9. (Pubitemid 29329163)
70. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: Relation to the incidence rate of cervical carcinoma. Cancer 2000;88:2082-91. (Pubitemid 30233210)
71. Jee SH, Lee JE, Park JS. Polymorphism of codon 72 of p53 and environmental factors in the development of cervical cancer. Int J Gynaecol Obstet 2003;80:69-70. (Pubitemid 36071347)
72. Lee SA, Kim JW, Roh JW, Choi JY, Lee KM, Yoo KY, et al. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol 2004;93:14-8. (Pubitemid 38429543)
73. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: Effect of inter-laboratory variation. Int J Cancer 2000;87:528-33. (Pubitemid 30639812)
74. Dos Santos Oliveira Ldo H, Fernandez Ade P, Xavier BL, Machado Rodrigues Ede V, Cavalcanti SM. Analysis of the p53 gene and papillomavirus detection in smears from cervical lesions. Sao Paulo Med J 2002;120:20-2. (Pubitemid 43051587)
75. Van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 2000;81:317-25. (Pubitemid 30077274)
76. Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPVassociated cervical cancer. Mol Cell Biol Res Commun 2000;3:111-4. (Pubitemid 30252137)
77. Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, et al. TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1009-12. (Pubitemid 32844911)
78. Pegoraro RJ, Rom L, Lanning PA, Moodley M, Naiker S, Moodley J. P53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women. Int J Gynecol Cancer 2002;12:383-8. (Pubitemid 34839837)
79. Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, Contractor R, et al. HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol 2002;86:157-62. (Pubitemid 34953498)
80. Nagpal JK, Sahni S, Das BR. P53 codon 72 polymorphism and susceptibility to development of human papilloma virus-associated cervical cancer in Indian women. Eur J Clin Invest 2002;32:943-8. (Pubitemid 35478067)
81. Mitra S, Misra C, Singh RK, Panda CK, Roychoudhury S. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol 2005;58:26-31. (Pubitemid 40070492)
82. Arbel-Alon S, Menczer J, Feldman N, Glezerman M, Yeremin L, Friedman E. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 2002;12:741-4. (Pubitemid 35388043)
83. Qie M, Zhang Y, Wu J. Study on the relationship between cervical cancer and p53 codon 72 polymorphism. Hua Xi Yi Ke Da Xue Xue Bao 2002;33:274-5.
84. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003;36:279-83. (Pubitemid 37168568)
85. Wong YF, Chung TK, Cheung TH, Nobori T, Hampton GM, Wang VW, et al. p53 polymorphism and human papillomavirus infection in Hong Kong women with cervical cancer. Gynecol Obstet Invest 2000;50:60-3. (Pubitemid 30445758)
86. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 1998;58: 4585-6. (Pubitemid 28480619)
87. Nishikawa A, Fujimoto T, Akutagawa N, Iwasaki M, Takeuchi M, Fujinaga K, et al. p53 Polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int J Gynecol Cancer 2000;10:402-7.
88. Josefsson AM, Magnusson PK, Ylitalo N, Quarforth- Tubbin P, Ponten J, Adami HO, et al. p53 polymorphism and risk of cervical cancer. Nature 1998;396:531; author reply 532.
89. Gustafsson AC, Guo Z, Hu X, Ahmadian A, Brodin B, Nilsson A, et al. HPV-related cancer susceptibility and p53 codon 72 polymorphism. Acta Derm Venereol 2001;81:125-9. (Pubitemid 32662154)
90. Malcolm EK, Baber GB, Boyd JC, Stoler MH. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk. Mod Pathol 2000;13:373-8. (Pubitemid 30225225)
91. Madeleine MM, Shera K, Schwartz SM, Daling JR, Galloway DA, Wipf GC, et al. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev 2000;9:225-7. (Pubitemid 30111949)
92. Inserra P, Abrahamsen M, Papenfuss M, Giuliano AR. Ethnic variation of the P53 codon 72 polymorphism, HPV persistence, and cervical cancer risk. Int J STD AIDS 2003;14:800-4. (Pubitemid 37533138)
93. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998;352:871-2. (Pubitemid 28416721)
94. Lanham S, Campbell I, Watt P, Gornall R. p53 polymorphism and risk of cervical cancer. Lancet 1998;352:1631. (Pubitemid 28515268)
95. Giannoudis A, Graham DA, Southern SA, Herrington CS. p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Int J Cancer 1999;83:66-9. (Pubitemid 29409479)
96. Brady CS, Duggan-Keen MF, Davidson JA, Varley JM, Stern PL. Human papillomavirus type 16 E6 variants in cervical carcinoma: Relationship to host genetic factors and clinical parameters. J Gen Virol 1999;80:3233-40.
97. Hayes VM, Hofstra RM, Buys CH, Hollema H, van der Zee AG. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet 1998;352:1756. (Pubitemid 28534966)
98. Govan VA, Loubser S, Saleh D, Hoffman M, Williamson AL. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency. Int J Immunogenet 2007;34:213-7. (Pubitemid 46763553)
99. Helland A, Borresen-Dale AL. p53 polymorphism and cervical cancer. Lancet 1999;354:1561-2.
100. Ngan HY, Liu VW, Liu SS. Risk of cervical cancer is not increased in Chinese carrying homozygous arginine at codon 72 of p53. Br J Cancer 1999;80:1828-9. (Pubitemid 29389641)
101. Hou MM, Xi MR, Cao ZY, Yang KX, Sun ZL. P53 codon 72 polymorphism in cervical cancers and its correlation with HPV16,18E6. Sichuan Da Xue Xue Bao Yi Xue Ban 2006;37:404-7.
102. Min-min H, Ming-rong X, Ze-yi C, Kai-xuan Y, Zhi-lin S. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. Int J Gynecol Cancer 2006;16:2004-8. (Pubitemid 44924363)
103. Yamashita T, Yaginuma Y, Saitoh Y, Kawai K, Kurakane T, Hayashi H, et al. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis 1999;20:1733-6. (Pubitemid 29410552)
104. Niwa Y, Hamajima N, Atsuta Y, Yamamoto K, Tamakoshi A, Saito T, et al. Genetic polymorphisms of p73 G4C14- to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 2004;205:55-60. (Pubitemid 38230139)
105. Tachezy R, Mikyskova I, Salakova M, Van Ranst M. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet 1999;105:564-6. (Pubitemid 30026033)
106. Baek WK, Cho JW, Suh SI, Suh MH, Shin DH, Cho CH, et al. p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women. J Korean Med Sci 2000;15:65-7.
107. Kim JW, Roh JW, Park NH, Song YS, Kang SB, Lee HP. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol 2001;184:55-8. (Pubitemid 32141642)
108. Tenti P, Vesentini N, Rondo Spaudo M, Zappatore R, Migliora P, Carnevali L, et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev 2000;9:435-8. (Pubitemid 30265788)
109. Cenci M, French D, Pisani T, Alderisio M, Lombardi AM, Marchese R, et al. p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Res 2003;23:1385-7. (Pubitemid 36754103)
110. Comar M, Molin GD, Guaschino S, Campello C. p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: A cross-sectional study from northeastern Italy. Eur J Obstet Gynecol Reprod Biol 2004;114:210-4. (Pubitemid 38622084)
111. Kucera E, Tong D, Reinthaller A, Leodolter S, Zeillinger R, Sliutz G. p53 polymorphism at codon 72-does it constitute a risk for squamous intraepithelial lesions and invasive cancer of the cervix in Central Europeans? Wien Klin Wochenschr 2000;112:817-20.
112. Pillai MR, Sreevidya S, Pollock BH, Jayaprakash PG, Herman B. Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. J Cancer Res Clin Oncol 2002;128:627-31. (Pubitemid 35435561)
113. Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 2003;252:117-24. (Pubitemid 37220740)
114. Abba MC, Villaverde LM, Gomez MA, Dulout FN, Laguens MR, Golijow CD. The p53 codon 72 genotypes in HPV infection and cervical disease. Eur J Obstet Gynecol Reprod Biol 2003;109:63-6. (Pubitemid 36724643)
115. Brenna SM, Silva ID, Zeferino LC, Pereira JS, Martinez EZ, Syrjanen KJ. Prognostic value of P53 codon 72 polymorphism in invasive cervical cancer in Brazil. Gynecol Oncol 2004;93:374-80. (Pubitemid 38507604)
116. Settheetham-Ishida W, Singto Y, Yuenyao P, Tassaneeyakul W, Kanjanavirojkul N, Ishida T. Contribution of epigenetic risk factors but not p53 codon 72 polymorphism to the development of cervical cancer in Northeastern Thailand. Cancer Lett 2004;210:205-11. (Pubitemid 38748691)
117. Settheetham-Ishida W, Kanjanavirojkul N, Kularbkaew C, Ishida T. Human papillomavirus genotypes and the p53 codon 72 polymorphism in cervical cancer of Northeastern Thailand. Microbiol Immunol 2005;49:417-21. (Pubitemid 40806066)
118. Li CY, Liu JH, Huang BJ. Correlation between P53 codon 72 polymorphism and tumorigenesis of cervical cancer. Ai Zheng 2004;23:1396-9.
119. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: Nodes of coordination in immune signalling networks. Nat Immunol 2009;10:348-55.
120. Carroll MC, Katzman P, Alicot EM, Koller BH, Geraghty DE, Orr HT, et al. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci USA 1987;84:8535-9. (Pubitemid 18033456)
121. Beutler B, Cerami A. The biology of cachectin/TNF: A primary mediator of the host response. Annu Rev Immunol 1989;7:625-55. (Pubitemid 19138027)
122. Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, et al. Tumor necrosis factor in solid tumors: Increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 1992;6:103-7. (Pubitemid 23000988)
123. Ghaderi M, Nikitina L, Peacock CS, Hjelmstrom P, Hallmans G, Wiklund F, et al. Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev 2000;9:1067-70.
124. Stanczuk GA, Sibanda EN, Tswana SA, Bergstrom S. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-alpha) gene and cervical cancer. Int J Gynecol Cancer 2003;13:148-53. (Pubitemid 37055469)
125. Govan VA, Constant D, Hoffman M, Williamson AL. The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer 2006;6:24.
126. Abrahamsson J, Carlsson B, Mellander L. Tumor necrosis factor-alpha in malignant disease. Am J Pediatr Hematol Oncol 1993;15:364-9.
127. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 1993;16:180-6. (Pubitemid 23123807)
128. Zwirner NW, Fernandez-Vina MA, Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 1998;47:139-48. (Pubitemid 28059537)
129. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:1737-40. (Pubitemid 28164472)
130. Ota M, Katsuyama Y, Mizuki N, Ando H, Furihata K, Ono S, et al. Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): Allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian. Tissue Antigens 1997;49:448-54. (Pubitemid 27207749)
131. Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994;91:6259-63. (Pubitemid 24200639)
132. Santos AM, Sousa H, Pinto D, Portela C, Pereira D, Catarino R, et al. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 2006;42:958-63.
133. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53- inducible gene WAF1/CIP1. Oncogene 1994;9:3021-4. (Pubitemid 24296780)
134. Sun Y, Hildesheim A, Li H, Li Y, Chen JY, Cheng YJ, et al. No point mutation but a codon 31ser->arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): The polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 1995;4:261-7.
135. Roh J, Kim M, Kim J, Park N, Song Y, Kang S, et al. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett 2001;165: 59-62. (Pubitemid 32206658)
136. Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V, Ohnishi T. Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women. Int J Mol Med 2001;7:261-4.
137. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993;11:165-90. (Pubitemid 23115005)
138. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An auto-regulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
139. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by pro-inflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995;25:394-8.
140. Clerici M, Merola M, Ferrario E, Trabattoni D, Villa ML, Stefanon B, et al. Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection. J Natl Cancer Inst 1997;89: 245-50. (Pubitemid 27073762)
141. Chopra V, Dinh TV, Hannigan EV. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 1998;16:152-9. (Pubitemid 28158437)
142. Szoke K, Szalmas A, Szladek G, Veress G, Gergely L, Toth FD, et al. IL-10 promoter nt -1082A/G polymorphism and human papillomavirus infection in cytologic abnormalities of the uterine cervix. J Interferon Cytokine Res 2004;24:245-51. (Pubitemid 38526784)
143. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8. (Pubitemid 27050850)
144. Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, et al. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer 2001;94:792-4. (Pubitemid 33032825)
145. Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, et al. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett 2002;184: 57-63. (Pubitemid 34718107)
146. Govan VA, Carrara HR, Sachs JA, Hoffman M, Stanczuk GA, Williamson AL. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J Carcinog 2003;2:3.
147. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre) neoplastic cervical disease. Int J Gynecol Cancer 2005; 15(Suppl 3):282-90. (Pubitemid 43096595)
148. Farzaneh F, Roberts S, Mandal D, Ollier B, Winters U, Kitchener HC, et al. The IL-10 -1082G polymorphism is associated with clearance of HPV infection. BJOG 2006;113:961-4. (Pubitemid 44086926)
149. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, et al. Human methylenetetrahydrofolate reductase: Isolation of cDNA mapping and mutation identification. Nat Genet 1994;7:551. (Pubitemid 24308346)
150. Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996;89:571-7. (Pubitemid 26278868)
151. Stevenson RE, Schwartz CE, Du YZ, Adams MJ Jr. Differences in methylenetetrahydrofolate reductase genotype frequencies, between Whites and Blacks. Am J Hum Genet 1997;60:229-30. (Pubitemid 26427798)
152. Gerhard DS, Nguyen LT, Zhang ZY, Borecki IB, Coleman BI, Rader JS. A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. Gynecol Oncol 2003;90:560-5.
153. Piyathilake CJ, Macaluso M, Johanning GL, Whiteside M, Heimburger DC, Giuliano A. Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia. Anticancer Res 2000;20:1751-7. (Pubitemid 30628198)
154. Goodman MT, McDuffie K, Hernandez B, Wilkens LR, Bertram CC, Killeen J, et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 2001;10:1275-80. (Pubitemid 34027759)
155. Sull JW, Jee SH, Yi S, Lee JE, Park JS, Kim S, et al. The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol 2004;95:557-63. (Pubitemid 39592521)
156. Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Hum Genet 2005;116:247-54. (Pubitemid 40277235)
157. Lambropoulos AF, Agorastos T, Foka ZJ, Chrisafi S, Constantinidis TC, Bontis J, et al. Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett 2003;191:187-91. (Pubitemid 36255604)
158. Henao OL, Piyathilake CJ, Waterbor JW, Funkhouser E, Johanning GL, Heimburger DC, et al. Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. Int J Cancer 2005;113:991-7. (Pubitemid 40096879)
159. Piyathilake CJ, Azrad M, Macaluso M, Johanning GL, Cornwell PE, Partridge EE, et al. Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition 2007;23:229-35. (Pubitemid 46367568)
160. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma: An update. Ann N Y Acad Sci 1998;856:22-32.
161. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000;61:863-6.
162. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, Munger K, et al. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 2003;107: 407-15. (Pubitemid 37266461)
163. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001;2:108-15. (Pubitemid 33707927)
164. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992;13:265-70.
165. Riethdorf L, Riethdorf S, Gutzlaff K, Prall F, Loning T. Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol 1996;149: 1469-76. (Pubitemid 26363953)
166. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R, Rosl F. Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer 1999;82:6-11. (Pubitemid 29266098)
167. Loannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al. Effects of CCR5- Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001;135:782-95. (Pubitemid 33051262)
168. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-65. (Pubitemid 27366682)
169. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, et al. Effects of CCR5- Delta32 and CCR2-64I alleles on HIV-1 disease progression: The protection varies with duration of infection. AIDS 2003;17:377-87. (Pubitemid 36223262)
170. Doms RW, Peiper SC. Unwelcomed guests with master keys: How HIV uses chemokine receptors for cellular entry. Virology 1997;235:179-90. (Pubitemid 27394330)
171. Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S, Tashiro K. C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2003;145:135-8. (Pubitemid 37485974)
172. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004;41:e59.
173. Chatterjee K, Dandara C, Hoffman M, Williamson AL. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer 2010;10:278.
174. Coelho A, Matos A, Catarino R, Pinto D, Sousa H, Pereira D, et al. The influence of chemokine receptor CCR2 genotypes in the route to cervical carcinogenesis. Gynecol Obstet Invest 2007;64:208-12. (Pubitemid 350099006)
175. Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C, et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol 2005;96: 760-4. (Pubitemid 40255498)
176. Zheng B, Wiklund F, Gharizadeh B, Sadat M, Gambelunghe G, Hallmans G, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res 2006;26:3669-74. (Pubitemid 44701441)
177. Ivansson EL, Gustavsson IM, Magnusson JJ, Steiner LL, Magnusson PK, Erlich HA, et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer 2007;121:2451-7. (Pubitemid 350022414)
178. Zornig M, Hueber A, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001;1551:F1-37. (Pubitemid 32925236)
179. Ando K, Hiroishi K, Kaneko T, Moriyama T, Muto Y, Kayagaki N, et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997;158:5283-91. (Pubitemid 127681233)
180. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-82. (Pubitemid 27512871)
181. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-30. (Pubitemid 36950998)
182. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183-8. (Pubitemid 34601951)
183. Lai HC, Lin WY, Lin YW, Chang CC, Yu MH, Chen CC, et al. Genetic polymorphisms of FAS and FASL (CD95/ CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005;99:113-8.
184. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221-5.
185. Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes 2009;2:238.
186. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-8. (Pubitemid 36026132)
187. Dybikowska A, Sliwinski W, Emerich J, Podhajska AJ. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Int J Mol Med 2004;14:475-8.
188. Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer 2004;112:1084-5. (Pubitemid 39507020)
189. Sergentanis TN, Economopoulos KP. Association of two CASP8 polymorphisms with breast cancer risk: A metaanalysis. Breast Cancer Res Treat 2010;120:229-34.
190. Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, et al. A sixnucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-13. (Pubitemid 46676113)
191. Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med 2005;202:967-74. (Pubitemid 41396896)
192. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: Pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003;14:805-14. (Pubitemid 37500732)
193. Goodman MT, McDuffie K, Hernandez B, Bertram CC, Wilkens LR, Guo C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol 2001;81:263-9. (Pubitemid 32424172)
194. Juarez-Cedillo T, Vallejo M, Fragoso JM, Hernandez-Hernandez DM, Rodriguez-Perez JM, Sanchez-Garcia S, et al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer 2007;43:1590-5. (Pubitemid 46891804)
195. Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR. Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer: Associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol 2006;101:411-7. (Pubitemid 43729981)
196. Taskiran C, Aktas D, Yigit-Celik N, Alikasifoglu M, Yuce K, Tuncbilek E, et al. CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol 2006;101:503-6.
197. Chen C, Madeleine MM, Weiss NS, Daling JR. Glutathione S-transferase M1 genotypes and the risk of squamous carcinoma of the cervix: A population-based case-control study. Am J Epidemiol 1999;150:568-72. (Pubitemid 29426900)
198. Sharma A, Sharma JK, Murthy NS, Mitra AB. Polymorphisms at GSTM1 and GSTT1 gene loci and susceptibility to cervical cancer in Indian population. Neoplasma 2004;51:12-6. (Pubitemid 38250150)
199. Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S, Cooper J, et al. The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 1992;2:246-58.
200. Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, et al. Susceptibility and outcome in oral cancer: Preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998;8:433-9. (Pubitemid 28475307)
201. Warwick A, Sarhanis P, Redman C, Pemble S, Taylor JB, Ketterer B, et al. Theta class glutathione S-transferase GSTT1 genotypes and susceptibility to cervical neoplasia: Interactions with GSTM1, CYP2D6 and smoking. Carcinogenesis 1994;15:2841-5.
202. Sobti RC, Kaur S, Kaur P, Singh J, Gupta I, Jain V, et al. Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India. Cancer Genet Cytogenet 2006;166:117-23.
203. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
204. Ueda M, Hung YC, Terai Y, Saito J, Nunobiki O, Noda S, et al. Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis. Gynecol Oncol 2005;96:736-40. (Pubitemid 40255494)